Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,086actual
Sites
56
Countries
Bulgaria, Croatia, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-20 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease (CKD)
Primary outcomes
what the primary-completion date above is the date OFDapagliflozin utilisation: to describe characteristics among patients who are treated with dapagliflozin.
measured 12 months prior to the index date
ANTHROPOMETRIC CHARACTERISTICS at study index date
measured 12 months prior to the index date
CLINICAL CHARACTERISTICS
measured 12 months prior to the index date
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed